Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on new anticoagulants.

Lori-Ann Linkins1, Jeffrey I Weitz

  • 1McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada L8V 1C3.

Current Drug Targets. Cardiovascular & Haematological Disorders
|December 20, 2003
PubMed
Summary

New anticoagulants are being developed to improve prevention and treatment of blood clots, aiming to overcome limitations of current therapies like heparin. These novel agents target specific molecular pathways in coagulation and are progressing through clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

From Rapid Reviews to Rapid Living Evidence Synthesis: Lessons From COVID-19 Vaccine Effectiveness Reviews for Canadian Public Health Decision-Making.

Campbell systematic reviews·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Venous and arterial thromboembolism pose significant clinical challenges.
  • Existing anticoagulants, such as heparin and vitamin K antagonists, have limitations including narrow therapeutic windows and monitoring requirements.

Purpose of the Study:

  • To review the mechanisms of venous and arterial thrombogenesis.
  • To discuss the complex regulation of the coagulation cascade.
  • To identify molecular targets for novel anticoagulant therapies.

Main Methods:

  • Literature review of thrombogenesis and coagulation pathways.
  • Analysis of molecular targets for anticoagulant drug development.
  • Review of clinical trial data for new anticoagulant agents.

Main Results:

  • Several novel anticoagulants targeting specific coagulation factors are in advanced clinical development.
  • These agents aim to offer improved efficacy and safety profiles compared to traditional anticoagulants.
  • Understanding of coagulation regulation has identified key molecular targets for intervention.

Conclusions:

  • New anticoagulant drugs are poised to significantly alter the management of thromboembolic disorders.
  • These agents offer potential advantages in preventing and treating both venous and arterial thromboembolism.
  • Clinical practice will likely evolve with the integration of these novel anticoagulants.

Related Experiment Videos